Composition for the transdermal delivery of fentanyl
OwnerAdam S. Cantor, Terrance W. Ocheltree +1inventors
InventorsAdam S. Cantor, Terrance W. Ocheltree, Cynthia A. Robles
Life of this patent
Estimating the term…
Abstract
A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.
Claims33
A transdermal drug delivery composition comprising
- (a) a copolymer comprising
- (i) one or more A monomers selected from the group consisting of alkyl acrylates containing 4 to 12 carbon atoms in the alkyl group and alkyl methacrylates containing 4 to 12 carbon atoms in the alkyl group;
- and
- (ii) one or more ethylenically unsaturated B monomers copolymerizable with the A monomer;
- and
- (b) about 8% to about 30% by weight fentanyl based on the total weight of the composition.
A pressure sensitive adhesive composition for the transdermal delivery of fentanyl comprising:
- (a) a polymer;
- (b) fentanyl;
- and
- (c) a delivery enhancing adjuvant selected from the group consisting of methyl laurate, tetraglycol, and mixtures thereof.
A method of providing sustained analgesia to a mammal comprising delivering fentanyl to a mammal via a transdermal drug delivery device in an amount of about 0.5 to about 5.0 mg/day thereby causing the serum concentration of fentanyl in the mammal to be about 0.2 to about 10 ng/mL for a period of time from about 4 to about 14 days.
Dependencies are inferred from the claim text.